Form: 3

Initial statement of beneficial ownership of securities

December 22, 2022

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
MCNULTY JAMES A
(Last) (First) (Middle)
C/O INHIBITOR THERAPUTICS, INC.,
900 WEST PLATT ST, SUITE 200
(Street)
TAMPA FL 33606
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/13/2022 		3. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 548,000 D
Common Stock 85,627,069 I See Footnotes(1)(2)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Options 07/01/2016 07/01/2026 Common Stock 150,000 0.24 D
Explanation of Responses:
1. These shares represent 6,000,000 shares of common stock held by Hopkins Capital Group II, LLC ("HCG II LLC") and 79,627,069 shares of common stock held by Hedgepath, LLC ("HP LLC").
2. Mr. McNulty is the manager of HCG II LLC and HP LLC. As such, Mr. McNulty may be deemed to have beneficial ownership of the common stock held by HCG II LLC and HP LLC through his voting and dispositive control over HCG II LLC and HP LLC. Mr. McNulty disclaims any beneficial ownership of the reported shares held by HCG II LLC and HP LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
Remarks:
Chief Financial Officer, Treasurer, Secretary of the Company
/s/ James McNulty 12/22/2022
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.